Evommune, Inc.
13 articles about Evommune, Inc.
-
Evommune Closes $50 Million Series B Financing to Advance Broad Pipeline of Therapies to Treat Chronic Inflammatory Diseases
4/26/2023
Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat inflammatory diseases, today announced the completion of a $50 million Series B financing.
-
Evommune’s Human Tissue-based Approach Enables Discovery and Development of Safer, Innovative Chr...
10/12/2022
Evommune’s novel human tissue-based assay system is proving to be a key differentiator as the company develops therapies to control chronic inflammation in autoimmune diseases. -
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
Evommune Announces Appointment of Dr. Jeegar Patel as Chief Scientific Officer
10/3/2022
Evommune, Inc. announced the appointment of Jeegar Patel, Ph.D., as Chief Scientific Officer.
-
Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis
9/28/2022
Evommune, Inc. today announced enrollment of the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD).
-
Entering the second half of 2022, biopharma and life sciences companies from across the globe strengthen their leadership teams with new additions to the c-suite.
-
Evommune Announces Appointment of Greg Moss as Chief Corporate Strategy and Legal Officer
6/27/2022
Evommune, Inc., a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced the appointment of Gregory S. Moss, Esq. , as chief corporate strategy and legal officer.
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Evommune Announces Appointment of Kyle Carver as Chief Financial Officer
3/22/2022
Evommune, Inc., a clinical stage, biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced the appointment of Kyle Carver as chief financial officer.
-
Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers
3/21/2022
Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Evommune to Present at the 2021 American College of Toxicology Annual Meeting and the Annual Dermatology Drug Development Summit for Inflammatory Diseases
11/16/2021
Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, today announced that Hans Hofland, senior vice president, research, will present at the 42nd Annual Meeting of the American College of Toxicology and the 5th Annual Dermatology Drug Development Summit for Inflammatory Diseases this week.
-
Los Altos, Calif.-based Evommune closed on a Series A financing round worth $83 million. The financing round included Andera Partners, LSP, Pivotal bioVenture Partners.